Paul D. Smith

13.6k total citations · 3 hit papers
120 papers, 7.5k citations indexed

About

Paul D. Smith is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Paul D. Smith has authored 120 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Molecular Biology, 44 papers in Oncology and 38 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Paul D. Smith's work include Melanoma and MAPK Pathways (31 papers), Lung Cancer Treatments and Mutations (30 papers) and PI3K/AKT/mTOR signaling in cancer (18 papers). Paul D. Smith is often cited by papers focused on Melanoma and MAPK Pathways (31 papers), Lung Cancer Treatments and Mutations (30 papers) and PI3K/AKT/mTOR signaling in cancer (18 papers). Paul D. Smith collaborates with scholars based in United Kingdom, United States and France. Paul D. Smith's co-authors include Simon J. Cook, Matthew J. Sale, Elaine Kilgour, Wolf Reik, A. N. Brooks, Christopher J. Caunt, Wendy Dean, Armelle Logié, Nicolas Floc’h and Pasi A. Jänne and has published in prestigious journals such as Chemical Reviews, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Paul D. Smith

117 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

2012 512 citations Paul D. Smith et al. profile →
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

2015 431 citations Paul D. Smith, Simon J. Cook et al. profile →
Challenges and Opportunities in Cancer Drug Resistance

2020 330 citations Paul D. Smith et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul D. Smith United Kingdom	45	5.1k	2.4k	1.4k	1.4k	791	120	7.5k
Giuseppe Viglietto Italy	48	5.4k 1.1×	2.3k 0.9×	803 0.6×	1.6k 1.1×	591 0.7×	150	8.2k
Vladimir Lazar France	46	4.1k 0.8×	2.1k 0.9×	954 0.7×	2.1k 1.5×	607 0.8×	133	7.4k
Lisa M. Butler Australia	41	4.0k 0.8×	1.6k 0.7×	1.8k 1.2×	2.1k 1.5×	239 0.3×	149	6.7k
Anne‐Marie Mes‐Masson Canada	50	4.4k 0.9×	2.7k 1.1×	1.2k 0.8×	1.9k 1.4×	639 0.8×	272	9.1k
Goli Samimi United States	31	2.6k 0.5×	2.3k 1.0×	534 0.4×	1.7k 1.2×	549 0.7×	65	5.8k
Hal W. Hirte Canada	45	3.2k 0.6×	3.7k 1.5×	1.3k 0.9×	977 0.7×	1.0k 1.3×	156	8.1k
Alan K. Meeker United States	57	5.2k 1.0×	3.6k 1.5×	2.6k 1.8×	1.6k 1.1×	387 0.5×	178	11.1k
Rugang Zhang United States	51	5.8k 1.1×	2.0k 0.8×	851 0.6×	1.3k 0.9×	630 0.8×	145	8.4k
Ben Ho Park United States	43	5.2k 1.0×	2.5k 1.0×	1.5k 1.0×	2.2k 1.6×	660 0.8×	142	8.0k
Paul Haluska United States	38	2.5k 0.5×	2.0k 0.8×	618 0.4×	1.1k 0.8×	346 0.4×	114	4.9k

Countries citing papers authored by Paul D. Smith

Since Specialization

Citations

This map shows the geographic impact of Paul D. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul D. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul D. Smith more than expected).

Fields of papers citing papers by Paul D. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul D. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul D. Smith. The network helps show where Paul D. Smith may publish in the future.

Co-authorship network of co-authors of Paul D. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Paul D. Smith. A scholar is included among the top collaborators of Paul D. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul D. Smith. Paul D. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Channathodiyil, Prasanna, et al.. (2022). Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance. NAR Cancer. 4(4). zcac032–zcac032. 3 indexed citations

Ponz‐Sarvisé, Mariano, Vincenzo Corbo, Hervé Tiriac, et al.. (2019). Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Clinical Cancer Research. 25(22). 6742–6755. 41 indexed citations

Beloueche‐Babari, Mounia, Markela Koniordou, Harold G. Parkes, et al.. (2017). MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy. Cancer Research. 77(21). 5913–5924. 105 indexed citations

Linley, Adam J., Dean E. Hammond, Fiona E. Hood, et al.. (2017). New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome. Cancer Research. 78(1). 15–29. 117 indexed citations

Brant, Roz, Alan Sharpe, Jonathan R. Dry, et al.. (2016). Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors. Clinical Cancer Research. 23(6). 1471–1480. 17 indexed citations

Delpuech, Oona, Claire Rooney, Lorraine Mooney, et al.. (2016). Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547. Molecular Cancer Therapeutics. 15(11). 2802–2813. 18 indexed citations

Bartholomeusz, Chandra, Xuemei Xie, Kimie Kondo, et al.. (2015). MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Molecular Cancer Therapeutics. 14(12). 2773–2781. 59 indexed citations

Bola, Becky M., Amy L. Chadwick, Filippos Michopoulos, et al.. (2014). Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport. Molecular Cancer Therapeutics. 13(12). 2805–2816. 155 indexed citations

Gopal, Y.N. Vashisht, Helen Rizos, Guo Chen, et al.. (2014). Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma. Cancer Research. 74(23). 7037–7047. 148 indexed citations

10.

Zhang, Weiguo, Vivian Ruvolo, Gao Chen, et al.. (2014). Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells. Molecular Cancer Therapeutics. 13(7). 1848–1859. 30 indexed citations

11.

Bid, Hemant K., Doris A. Phelps, Linlin Xiao, et al.. (2013). Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma. Clinical Cancer Research. 19(24). 6716–6729. 49 indexed citations

12.

Cumberbatch, Marie, Ximing Tang, Garry Beran, et al.. (2013). Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma. Clinical Cancer Research. 20(3). 595–603. 22 indexed citations

13.

Polański, Radosław, Cassandra L. Hodgkinson, Alberto Fusi, et al.. (2013). Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer. Clinical Cancer Research. 20(4). 926–937. 282 indexed citations

14.

Holt, Sarah V., Armelle Logié, Barry R. Davies, et al.. (2012). Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055). Cancer Research. 72(7). 1804–1813. 70 indexed citations

15.

Gopal, Y.N. Vashisht, Wanleng Deng, Scott E. Woodman, et al.. (2010). Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf- Mutant Human Cutaneous Melanoma Cells. Cancer Research. 70(21). 8736–8747. 177 indexed citations

16.

Banerji, Udai, D. Ross Camidge, Henk M.W. Verheul, et al.. (2010). The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer. Clinical Cancer Research. 16(5). 1613–1623. 176 indexed citations

17.

Garon, Edward B., Richard S. Finn, Wylie Hosmer, et al.. (2010). Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines. Molecular Cancer Therapeutics. 9(7). 1985–1994. 49 indexed citations

18.

Shannon, Aoife M., Brian A. Telfer, Paul D. Smith, et al.. (2009). The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts. Clinical Cancer Research. 15(21). 6619–6629. 42 indexed citations

19.

Davies, Barry R., Armelle Logié, Jennifer S. McKay, et al.. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Molecular Cancer Therapeutics. 6(8). 2209–2219. 322 indexed citations

20.

Constância, Miguel, Emily Angiolini, Ionel Sandovici, et al.. (2005). Adaptation of nutrient supply to fetal demand in the mouse involves interaction between the Igf2 gene and placental transporter systems. Proceedings of the National Academy of Sciences. 102(52). 19219–19224. 245 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact